2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Herbst R, John T, Grohé C, Goldman J, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn M, Kowalski D, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu Y. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer. Nature Medicine 2025, 31: 1958-1968. PMID: 40097663, PMCID: PMC12176615, DOI: 10.1038/s41591-025-03577-y.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseDisease-free survivalNon-small-cell lung cancerDisease-free survival eventsEvent-free rateAdjuvant osimertinibOsimertinib treatmentStage IB-IIIA non-small-cell lung cancerLung cancerOverall survival improvementEvent-free statusPosttreatment follow-upExploratory post hoc analysisYear adjuvant treatmentPost hoc analysisDFS eventsOsimertinib groupResidual diseaseTreatment discontinuationPlacebo groupAdjuvant therapyAdjuvant treatmentSurvival improvementOsimertinibFollow-up
2024
1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Riess J, Miao J, Wheatley-Price P, Reckamp K, Kozono D, Redman M, Edelman M, Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Gandara D, Sokol E, Borghaei H, Gray J, Herbst R, Kelly K. 1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A. Annals Of Oncology 2024, 35: s832-s833. DOI: 10.1016/j.annonc.2024.08.1366.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply